When does semaglutide peak, and what does that mean for you?

What happens to semaglutide's levels in the first 72 hours after a dose?

After a subcutaneous injection, semaglutide is absorbed slowly from the tissue beneath the skin. Plasma concentration climbs gradually, reaching its peak (the pharmacokinetic term is Cmax) somewhere between 24 and 72 hours post-injection. The broad window reflects real biological variation: the abdomen tends to absorb slightly faster than the thigh, and individual factors like skin thickness and local circulation play a small role too.

During this rising phase, the medicine is binding to GLP-1 receptors in the gut and brain, slowing gastric emptying and dampening the hunger signals that normally drive eating. Many people find that the days immediately following their injection are when appetite suppression feels strongest, and that by day six or seven (just before the next dose) there is a mild fade. That fade is normal and is one reason the dosing interval is fixed at seven days rather than ten.

The NHS patient information page on semaglutide describes the once-weekly injection schedule and the absorption pathway in plain language if you want a reliable overview of how the medicine is taken.

Nothing about this peak-and-fade pattern means the dose is failing. It is simply the pharmacokinetics of a long-acting molecule doing exactly what the trials expected.

When does Wegovy reach a steady state, and why does it matter?

A single dose does not deliver the full picture. Because semaglutide's half-life is roughly seven days, each new injection arrives before the previous one has fully cleared. The result is accumulation: levels after dose two are higher than after dose one, levels after dose three higher still. After approximately four to five weekly injections at the same dose, incoming drug and outgoing drug reach a balance, steady state.

Steady state is clinically important because it is when the medicine is doing most of its consistent work. The appetite suppression, the slowed digestion, and the influence on blood sugar regulation are most stable once the body is no longer playing catch-up with rising levels. This is part of why the dose-escalation schedule exists: starting at a lower dose allows the body to adapt to the gastrointestinal effects before steady-state levels at a higher dose are reached.

For Wegovy specifically, the escalation pathway moves through several dose steps before reaching the maintenance dose, with the prescriber guiding that process. If you are curious about what the semaglutide peak looks like across the escalation schedule, understanding that pattern helps explain why the transition between doses can bring a temporary return of nausea, as the body adjusts to a new, higher steady state.

It also explains why stopping treatment, even briefly, matters. Miss several doses and blood levels fall substantially before the next injection, which can change how you feel when you restart.

Does the peak timing differ between the injection and the tablet?

It does, meaningfully. The semaglutide in Wegovy injections bypasses the digestive system entirely, which is why subcutaneous absorption produces that reliable 24–72 hour peak. Oral semaglutide (licensed in the UK in June 2026 as Wegovy tablets) works differently. It is co-formulated with an absorption enhancer and taken first thing in the morning on an empty stomach; the tablet must be swallowed with a small amount of plain water and nothing else consumed for at least 30 minutes afterwards. Oral bioavailability is lower than with injections, so the tablet is taken daily rather than weekly and at higher mg doses to achieve comparable circulating levels. If you want a closer look at how semaglutide peak time compares between the two formats, the once-daily tablet produces a much flatter peak-and-trough pattern than the once-weekly injection, which some people find makes the mid-week appetite fade less noticeable.

If you are weighing up the injection versus the tablet, a useful place to start is the weight-loss treatment overview, which sets out both options. A prescriber can talk through which format suits your routine.

Does knowing the peak timing change how you should use semaglutide?

For most people, the honest answer is: not dramatically. The injection is taken once a week on the same day, and the clinical advice is to keep that day consistent regardless of whether you feel the appetite effects more on day two or day three. Trying to time meals or activity to coincide with the peak concentration is not part of the licensed guidance, and the prescriber and the Patient Information Leaflet are the right sources for any questions about how to fit the medicine into your week.

What the peak timing does usefully explain is a few common experiences: why hunger tends to return just before the next injection, why the first week at a new dose can feel stronger than subsequent weeks at the same dose, and why the medicine needs several weeks before its full effect is apparent. A closer look at when semaglutide is at its peak can help make sense of these experiences, and the NICE appraisal of semaglutide for weight management (TA875) notes that the clinical assessment of response typically happens at six months, which only makes sense in the context of a medicine that builds over weeks rather than delivering its full effect after a single dose.

If you have questions about your own experience of the medicine, the aftercare team at nume is available seven days a week. And if you are still at the stage of considering whether semaglutide is right for you, understanding the cost context is a practical next step before starting your free consultation.